Faron Pharmaceuticals OY (FARN) NPV
45.00p
(15.79%)
- Add to watchlist
- Create an alert
- This stock can be held in a
45.00p
(15.79%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
45.00p
(15.79%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
285.00p
340.00p
362.50p
£227.00 million
285.00p
300.00p
227.00p
n/a
25.00p (9.62%) Previous:
25.00p
7,073
n/a
1,000
Performance
| 1 week 1W | 26.92% | 1 year 1Y | 8.33% |
|---|---|---|---|
| 1 month 1M | 22.22% | 2 years 2Y | 11.86% |
| 3 months 3M | 2.94% | 3 years 3Y | 20% |
| 6 months 6M | 26.44% | 5 years 5Y | 392.54% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
| Year ending: | 31/12/2022 | 31/12/2021 |
|---|---|---|
| Revenue (€m) | n/a | n/a |
| Profit before tax (€m) | (28.73) | (21.18) |
| Adjusted EPS (¢): | (52.00) | (42.00) |
| P/E ratio | n/a | n/a |
| PEG | n/a | n/a |
| EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: Euro
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Faron publishes cancer immunotherapy study findings
7 December 2023 11:01
-
Faron reveals details of next stage of bexmarilimab study
6 November 2023 10:31
-
Faron Pharmaceuticals upbeat on latest data in blood cancer trials
11 October 2023 14:53
-
Grant of options
4 December 2023 07:00
-
Faron Initiates Phase 2 Part of BEXMAB Study
6 November 2023 08:13
-
Faron Initiates Phase 2 Part of BEXMAB Study
6 November 2023 07:00
Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.